Balaxi Pharmaceuticals Share Price

    NSE
    50.04
    +0.18 (2.02%)
    BALAXI • 11 Jul, 2025 | 11:18 AM
    BUY

    1Y Annualised Return

    -57.67%

    3Y Annualised Return

    -13.26%

    5Y Annualised Return

    13.90%

    The current prices are delayed, login or Open Demat Account for live prices.

    Balaxi Pharmaceuticals Stock Performance

    1W Return1.26
    1Y Return-57.58
    Today's Low49.73
    Prev. Close49.86
    Mkt Cap (Cr.)275.26
    1M Return-8.30
    3Y Return-33.40
    52-Week High129.44
    Open50.10
    PE Ratio76.71
    6M Return-30.73
    Today's High50.3
    52-Week Low48.53
    Face Value2

    Balaxi Pharmaceuticals Company background

    Founded in: 1942
    Managing director: Ashish Maheshwari
    Balaxi Ventures Limited was formerly incorporated in the name of The Anandam Rubber Company Limited on September 28, 1942. The Company changed its name from The Anandam Rubber Company Limited to Balaxi Ventures Limited on August 08, 2017. The Company incorporated with a basic objective of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 201819 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 201819.Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP.The Company expanded its presence by establishing a central distribution warehouse in Guatemala, marking its entry into the third geography. This expansion helped in strengthening the distribution network and a wider customer base in 2019. In FY 2023, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations inthe Central African Republic.

    As of 11 Jul, 2025, Balaxi Pharmaceuticals share price is ₹50. The stock opened at ₹50.1 and had closed at ₹49.9 the previous day. During today’s trading session, Balaxi Pharmaceuticals share price moved between ₹49.73 and ₹50.30, with an average price for the day of ₹50.02. Over the last 52 weeks, the stock has recorded a low of ₹48.53 and a high of ₹129.44. In terms of performance, Balaxi Pharmaceuticals share price has declined by 30.7% over the past six months and has declined by 57.67% over the last year.

    Read More
    Balaxi Pharmaceuticals SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹49,32,625 (-24.11%)
    Daily SIP of 25,000 would have become 49,32,625 in 1 year with a gain of -15,67,374 (-24.11%)
    View details of Market Depth

    Balaxi Pharmaceuticals Fundamental

    Market Cap (in crs)

    275.26

    Face Value

    2

    Turnover (in lacs)

    19.46

    Key Metrics

    Qtr Change %
    Near 52W Low of ₹48.53
    -25.1
    Dividend yield 1yr %
    0

    Balaxi Pharmaceuticals Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Balaxi Pharmaceuticals Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    76.27 Cr
    73.29 Cr
    77.38 Cr
    65.62 Cr
    59.83 Cr
    Balaxi Pharmaceuticals Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    288.84 Cr
    238.65 Cr
    339.07 Cr
    284.36 Cr
    233.56 Cr
    48.44 Cr
    Balaxi Pharmaceuticals Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    8.64 Cr
    5.36 Cr
    4.59 Cr
    6.48 Cr
    10.93 Cr
    Balaxi Pharmaceuticals Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    25.07 Cr
    -2.39 Cr
    45.96 Cr
    47.66 Cr
    38.14 Cr
    6.1 Cr

    Balaxi Pharmaceuticals Result Highlights

    • Balaxi Pharmaceuticals Ltd reported a 24.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 27.9%.

    • Its expenses for the quarter were down by 33.1% QoQ and 31.4% YoY.

    • The net profit increased 103.9% QoQ and increased 34.9% YoY.

    • The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 10.4 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Balaxi Pharmaceuticals

    Promoter
    66%
    Foreign Institutions
    16%
    Public
    18%
    Promoter
    66%
    Foreign Institutions
    16.5%
    Public
    17.5%
    Promoter
    66%
    Foreign Institutions
    16.5%
    Public
    17.5%
    Promoter
    66%
    Foreign Institutions
    16.9%
    Public
    17.1%
    Promoter
    66.9%
    Foreign Institutions
    17.2%
    Public
    15.9%
    Promoter
    71.2%
    Foreign Institutions
    18.6%
    Public
    10.2%

    Balaxi Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    50.04
    Current Price
    Bullish Moving Averages
    6
    Bearish Moving Averages
    10
    5Day EMA
    49.70
    10Day EMA
    49.80
    12Day EMA
    49.80
    20Day EMA
    50.20
    26Day EMA
    50.70
    50Day EMA
    52.80
    100Day EMA
    58.30
    200Day EMA
    68.80
    5Day SMA
    49.60
    10Day SMA
    49.60
    20Day SMA
    49.90
    30Day SMA
    50.80
    50Day SMA
    51.80
    100Day SMA
    57.40
    150Day SMA
    63.10
    200Day SMA
    70.10
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    609934 Rs
    739869 Rs
    Week Rs
    203795 Rs
    312956 Rs
    Month Rs
    291073 Rs
    490675 Rs
    49.98
    Pivot
    Resistance
    First Resistance
    50.42
    Second Resistance
    50.99
    Third Resistance
    51.43
    Support
    First Support
    49.41
    Second support
    48.97
    Third Support
    48.40
    Relative Strength Index
    43.70
    Money Flow Index
    26.23
    MACD
    -0.84
    MACD Signal
    -1.04
    Average True Range
    2.11
    Average Directional Index
    25.69
    Rate of Change (21)
    -8.50
    Rate of Change (125)
    -35.90
    Name
    Holding Percent
    UNICO GLOBAL OPPORTUNITIES FUND LIMITED
    8.29
    EBISU GLOBAL OPPORTUNITIES FUND LIMITED
    7.73

    Balaxi Pharmaceuticals Share Price FAQs

    Balaxi Pharmaceuticals share price in the past 1-year return was -57.57. The Balaxi Pharmaceuticals share hit a 1-year low of Rs. 48.53 and a 1-year high of Rs. 129.44.

    The market cap of Balaxi Pharmaceuticals is Rs. 275.26 Cr. as of 11/7/2025.

    The PE ratios of Balaxi Pharmaceuticals is 76.7 as of 11/7/2025.

    The PB ratios of Balaxi Pharmaceuticals is 2.15 as of 11/7/2025

    You can easily buy Balaxi Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Balaxi Pharmaceuticals share price is ₹129.44 and ₹48.53 as of 11/7/2025.

    Please be aware that Balaxi Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.27
    -0.70 (-1.06%)
    135.59
    -1.54 (-1.12%)
    688.45
    -7.15 (-1.03%)
    2,559.10
    -21.90 (-0.85%)
    160.97
    -8.67 (-5.11%)
    380.30
    -4.40 (-1.14%)
    159.98
    -0.68 (-0.42%)
    262.00
    -0.85 (-0.32%)
    406.85
    -6.65 (-1.61%)
    396.50
    -3.40 (-0.85%)
    Top Gainers
    2,522.90
    +114.50 (+4.75%)
    1,832.00
    +21.80 (+1.20%)
    2,415.70
    +14.30 (+0.60%)
    1,170.50
    +6.20 (+0.53%)
    2,463.60
    +12.40 (+0.51%)
    Top Losers
    3,291.10
    -90.90 (-2.69%)
    7,177.50
    -181.50 (-2.47%)
    258.80
    -6.25 (-2.36%)
    3,090.00
    -72.40 (-2.29%)
    1,929.30
    -35.20 (-1.79%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -